Loading
A GLP-1 receptor agonist used for type 2 diabetes and obesity that also slows the progression of chronic kidney disease, per the FLOW trial.
Semaglutide is a once-weekly injectable (Ozempic, Wegovy) or daily oral (Rybelsus) GLP-1 receptor agonist. Beyond glucose and weight effects, the FLOW trial (Perkovic et al., NEJM 2024) showed a 24% reduction in a composite kidney outcome and a 20% reduction in cardiovascular death in people with type 2 diabetes and CKD — establishing GLP-1 receptor agonists as a pillar of cardio-renal-metabolic therapy alongside SGLT2 inhibitors. Semaglutide reduces albuminuria by roughly 30-40%, is safe at low eGFR for kidney protection (dosing differs from the weight-loss indication at very low eGFR), and is generally continued across CKD stages. Gastrointestinal side effects and muscle-mass loss deserve monitoring; dose and indication should follow current labeling and guidelines.
A calculated value estimating the rate at which kidneys filter blood, used to diagnose and stage chronic kidney disease.
Albumin leaking into urine — the earliest and most important marker of kidney filter damage, measured by urine albumin-to-creatinine ratio (UACR).
Kidney damage caused by diabetes - the leading cause of kidney failure worldwide, driven by hyperfiltration, albuminuria, and progressive scarring.
Advertisement
ZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.